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Abstract
Background: The role of epidermal growth factor (EGF) and its receptor (EGFR) in the pathogenesis and
progression of various malignant tumors has long been known, but there is still disagreement concerning
prognostic significance of EGFR expression in clear cell renal cell carcinoma (CCRCC). The present study was
designed to analyze more objectively the protein EGFR expression in CCRCC and to compare its value with EGFR
gene copy number changes and clinicopathologic characteristics including patient survival.
Methods: The protein EGFR expression was analyzed immunohistochemically on 94 CCRCC, and gene copy
number alterations of EGFR by FISH analysis on 41 CCRCC selected according to distinct membrane EGFR staining.
Results: Membrane EGFR expression in tumor cells was heterogeneous with respect to the proportion of positive
cells and staining intensity. FISH analysis did not reveal EGFR gene amplification, while polysomy of chromosome 7
found in 41% was associated with higher EGFR membrane expression. Moreover, EGFR overexpression was
associated with a higher nuclear grade, larger tumor size and shorter patient’s survival, while there was no
connection with pathological stage.
Conclusion: In conclusion, the protein expression of EGFR had an impact on prognosis in patients with CCRCC,
while an increased copy number of chromosome 7 could be the possible reason for EGFR protein overexpression
in the absence of gene amplification.
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Background
The role of growth factors in the pathogenesis and pro-
gression of various malignant tumors has long been
known [1-3]. Among them, epidermal growth factor
(EGF) and its receptor (EGFR) play a central role. Speci-
fic ligands, EGF and related growth factors such as TGF
a, ampiregulin, betacellulin, neuregulins, epiregulin and
heparin binding growth factor bind to the extracellular
domain of EGFR resulting in receptor conformational
change. This structural change allows for receptor dimer-
ization and autophosphorylation of tyrosine kinase resi-
dues within the intracellular domain leading to activation
of the signal transduction pathways. EGFR tyrosine
phosphorylation triggers several signaling cascades,
including the RAS-MAPK, PI3K-Akt and STAT path-
ways. Together, these EGFR-induced signaling pathways
control gene transcription, cell cycle progression, cell
proliferation and survival, adhesion, angiogenesis, migra-
tion, and invasion [4].
EGFR may be deregulated following point mutations
occurring in the tyrosine kinase (TK) domain or protein
overexpression. Both mechanisms can constitutively acti-
vate EGFR in a ligand independent manner [5,6]. Several
reports indicate that an increased gene copy number of
EGFR or mutations within the genes responsible for
downstream signaling are important determinants of
response or resistance to anti-EGFR antibodies [7].
Evaluation of EGFR by immunohistochemistry as a
screening method on paraffin embedded tumor tissues
has been widely used recently, primarily to select patients
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for targeted therapies. However, at practical level,
immuno-determination of EGFR overexpression does not
seem to accurately predict response to EGFR targeted
therapies. It has been shown that only EGFR activating
mutations or gene amplification seem to have a strong
predictive value [8-10]. Although prognostic significance
of EGFR was confirmed in numerous studies [11-13], the
association between EGFR expression and prognosis in
clear cell renal cell carcinoma (CCRCC) is still controver-
sial [14-16]. Overexpression of EGFR in renal cell carci-
noma (RCC) has been shown in various research, ranging
from 40-80%. Evaluation of EGFR immunoexpression is
not yet standardized and different scoring systems have
been reported. Furthermore, positivity of staining in most
studies has been defined only upon the membranous
EGFR expression and cytoplasmic staining was not con-
sidered as positive. Pu at al suggests that different loca-
tions of EGFR expression may be associated with human
renal tumorigenesis [14-16].
Thus, the aim of the present study was to analyze pro-
tein expression of EGFR by immunohistochemistry and
to investigate the role of EGFR gene copy number
changes in relation to EGFR overexpression in this type
of renal cancer. Study parameters were compared with
common clinicopathologic characteristics including
patient survival. Thus, the aim of the present study was
to analyze protein expression of EGFR by immunohisto-
chemistry and to investigate the role of EGFR gene copy
number changes in relation to EGFR overexpression in
this type of renal cancer. Study parameters were com-
pared with common clinicopathologic characteristics
including patient survival.
Methods
Patients and tumor specimens
Tissue microarrays (TMA) were built from 94 archive
formalin fixed and paraffin embedded CCRCC tissues
from Department of Pathology, School of Medicine,
University of Rijeka, Rijeka, Croatia, collected consecu-
tively from 1989 to 1994. The representative areas on
the haematoxylin and eosin (HE) stained sections were
carefully selected and marked on corresponding paraffin
blocks [17]. From each primary carcinoma, two tissue
cores (1 mm in diameter) were obtained and arrayed in
a recipient paraffin block using MTA Booster OI man-
ual tissue arrayer (Alphelys, Plaisir, France).
Tumors were classified and staged according to the
WHO [18] and TNM classification of renal cell neo-
plasm [19]. Grading of CCRCC was assessed according
to the four-tiered system of Fuhrman et al. [20]. Clini-
copathologic data including age, gender, tumor size,
pathological T stage, nuclear grade and patient survival
are summarized in Table 1.
Immunohistochemistry and evaluation
Immunohistochemistry was performed on 4-μm thick par-
affin sections using EGFR mouse monoclonal antibody
(IgG1 clone 2-18 C9; pharm Dx™ ready to use kit Dako
Cytomation, Glostrup, Denmark) as primary antibody.
According to the manufacturer’s instructions, for EGFR
staining we employed antigen retrieval using proteinase K.
Standard immunohistochemistry procedure was per-
formed in Dako Autostainer Plus (DakoCytomation Color-
ado Inc, Fort Collins, CO, USA) according to the
manufacturer’s instructions, using appropriate DakoREAL
solutions (Dako, Glostrup, Denmark). Breast cancer tissues
served as a positive control of EGFR. Also, a negative con-
trol consisting of the omission of the primary antibody
was performed for each case.
EGFR staining patterns were designated as cytoplasmic
or membranous. The membranous pattern was further
classified as partial (discontinuous) (Figure 1a) or circum-
ferential (continuous) (Figure 1b) membrane positivity,
while staining intensity was graded as 0 for negative, 1+
for weak, 2+ for moderate, and 3+ for strong staining.
Evaluation of immunohistochemical staining was based
on histo score (H-score) that was calculated by multiply-
ing the intensity of EGFR staining with percentage of
tumor cells showing particular membranous staining pat-
tern [15]. Continuous H-score (cH-score) was considered
for only continuous (circumferential) staining of cell
membrane, while total H-score (tH-score) included any
membrane staining (continuous and discontinuous). For
the purpose of two-way statistical analysis, H-score was
determined as “low” or “high” using the median as the
cut-off value. The evaluation of immunostaining was per-
formed by one pathologist (G. Đ.), who was blinded for
clinical data. On statistical analysis, the mean value of
Table 1 Clinicopathological parameters of CCRCC (N = 94)
Patients age (years), median (range) 61 (27-82)
Gender, No. (%)
M 59 (62.8)
F 35 (37.2)
Tumor size (cm), median (range) 6.3 (1.8-17.5)
Fuhrman nuclear grade, No. (%)
1 12 (12.8)
2 40 (42.6)
3 22 (23.4)
4 20 (21.2)
Pathological T stage (pT), No. (%)
1 49 (52.1)
2 22 (23.4)
3 23 (24.5)
4 0 (0)
Patient survival (months), median (range) 64 (1-165)
CCRCC, clear cell renal cell carcinoma; M, male; F, female
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immunohistochemical staining of two tissue microarrays
was used.
EGFR fluorescent in situ hybridization (FISH)
Forty-one tumors with distinct membrane EGFR immu-
noexpression on at least 5% of tumor cells were selected
for FISH analysis, or more precisely, 14 tumors with
strong (3+) and 16 with moderate (2+) continuous mem-
brane staining, and 11 tumors with week (1+) continuous
and discontinuous membrane staining. Also, FISH analysis
was performed on the rest of the CCRCC sample in order
to assess EGFR gene copy number changes in all tumors
regardless of the EGFR membrane immunohistochemical
pattern.
Three-μm thick sections were cut from TMA paraffin
blocks and used for FISH analysis. For proteolytic TMA
slide pretreatment, a commercial kit was used (Paraffin pre-
treatment reagent kit, Vysis, Downers Grove, USA) accord-
ing to the manufacturer’s instructions. We used LSI EGFR
SpectrumOrange/CEP 7 SpectrumGreen probe (Abbott,
Vysis, Downers Grove, IL, USA), which hybridizes to the
EGFR gene (orange signal) and to the centromeric region
of chromosome 7 (green signal). Briefly, TMA sections
were deparaffinized in xylene substitute, rinsed in 100%
ethanol and air dried. Subsequently, slides were incubated
in 0.2 N HCl for 20 min, rinsed in 2xSSC, pH 7.0 and
immersed for 30 min in 1 M NaSCN solution pre-warmed
at 80°C. After proteinse digestion, slide denaturation (95°C
for 5 min) and hybridization (37°C overnight) were carried
out in HYBrite™ (Vysis, IL, USA). On the next day, the
slides were washed, counterstained with DAPI (Vysis,
Downers Grove, IL, USA) and examined under fluorescent
microscope (Olympus BX50, Tokyo, Japan).
At least 20 nuclei were analyzed from each tumor at
three representative tumor areas per two tissue cores.
Cells were selected for scoring according to morphological
criteria, where only those nuclei having an evident malig-
nant cytological appearance were scored. Small cells, over-
lapping or damaged nuclei were disregarded. A cell with a
normal number of copies of the EGFR gene or chromo-
some 7 status was characterized by 2 orange and 2 green
signals per nucleus. A tumor was characterized as polyso-
mic if there were more than two centromere 7 signals per
cell (polysomy) in more than 20% of tumor cells [21].
EGFR amplification was defined as the presence of the
oncogene/centromere ratio ≥ 2.0.
Statistical analysis
Statistical analysis was performed using Statistica soft-
ware (StatSoft, Inc., Tulsa, OK, USA). The distribution
Figure 1 EGFR protein and gene status in clear cell renal cell carcinoma. Immunohistochemical expression of EGFR protein, shown at lower
(×10) and higher magnification (×20), was designated as discontinuous or continuous membrane staining of different intensity: (a) weak and
moderate (+/++) discontinuous and continuous membrane immunostaining, and (b) strong continuous immunostaining (+++);. (c) chromosome
7 copy number was analyzed in tumor cells using fluorescence in situ hybridization (FISH) with an a-satellite DNA probe for chromosome 7
(centromere 7, green signal; EGFR gene, red signal); tumor nuclei showed disomy of chromosome 7 without EGFR gene amplification (d) tumor
nuclei showed polysomy with a greater number of red and green signals than in normal cells; (c and d magnification × 100).
Đorđević et al. Journal of Biomedical Science 2012, 19:40
http://www.jbiomedsci.com/content/19/1/40
Page 3 of 8
of data was tested for normality using Kolmogorov-
Smirnov test. Tumor size and chromosome 7 polysomy
were used as numerical data, while nuclear grade, patho-
logical T stage, EGFR H-score and chromosome 7 polys-
omy as categorical data were divided in two categories.
Pearson’s c2-test was used to assess the association of
EGFR H-score with nuclear grade and pathological T
stage, as well as to assess the association of EGFR stain-
ing intensity and chromosome 7 polysomy status in
CCRCC. Association between EGFR protein expression
and tumor size was defined with Mann-Whitney U-test.
One -way ANOVA served to compare the EGFR immu-
nohistochemical staining intensity and number of tumor
cells showing chromosome 7 polysomy. Association
between EGFR protein expression and overall patient
survival was estimated using Kaplan-Meier method,
while difference between survival rates was evaluated by
use of log-rank test. Multivariate analysis was performed
using Cox regression model. Statistical differences with
a p value less than 0.05 were considered significant.
Results
Immunohistochemical and FISH analysis of EGFR
expression
EGFR expression was largely undetected immunohisto-
chemically in normal renal tissue with occasional weak
basal cytoplasmic staining in proximal and distal tubules
but not in collecting ducts or blood vessels. In tumor cells,
cytoplasmic EGFR expression was very heterogeneous
showing a small proportion of positive cells with weak
intensity. More precisely, the cytoplasmic EGFR expres-
sion was found in 29/94 (30.8%) CCRCC tumors but ran-
ged from 2% to 10% of positive tumor cells; therefore, it
was not further commented.
Membrane EGFR expression in tumor cells was also het-
erogeneously distributed in respect to the proportion of
positive tumor cells and staining intensity. The median
percentage of membranous staining was 28.9%, ranging
from 0% to 100%. When the percentage of membrane
EGFR expression was combined with the intensity of
staining, the median value of tH-score and cH-score was
30 (0-257) and 15.6 (0-255), respectively. A representative
case with membranous EGFR expression in CCRCC is
shown in Figure 1a and 1b.
FISH analysis did not reveal any amplification of EGFR
gene in our cohort of CCRCC, while polysomy was
detected in 17 of 41 examined tumors (41.5%) (Figure 1c
and 1d). Chromosome 7 polysomy was found to be asso-
ciated with EGFR immunohistochemical expression
(Figure 2 and 3). The proportion of tumors showing chro-
mosome 7 polysomy was increasing with EGFR staining
intensity (p = 0.019) (Figure 2a). The EGFR staining inten-
sity was also related to the number of tumor cells with
chromosome 7 polysomy (p = 0.004) (Figure 2b).
In addition, comparison between EGFR FISH analysis
and protein expression (determined as percentage of
positive tumor cells, tH-score and cH-score) in CCRCC
was assessed (Figure 3). Statistical analysis showed sig-
nificant association between all EGFR immunohisto-
chemical staining categories and percentage of positive
tumor cells with chromosome 7 polysomy (Figure 3).
Comparison of EGFR protein and gene status with
clinicopathologic features
EGFR immunoexpression analysis showed association of
high %, tH-score and cH- score values with a higher
nuclear grade (p < 0.001, p < 0.001 and p = 0.006, respec-
tively) and larger tumors (p = 0.011, p = 0.002 and p =
0.01, respectively), while there was no association with
pathological T stage (Table 2). On contrary, chromosome
7 polysomy showed no association with any clinicopatho-
logical feature as well as patients’ survival. EGFR protein
Figure 2 Chromosome 7 polysomy in different groups of clear
cell renal cell carcinoma (CCRCC) regarding EGFR
immunohistochemical staining intensity: (a) the number of
tumors categorised as polysomic decreases with attenuation of
staining intensity (p = 0.019, Pearson’s c2-test). Black bars represent
percentage of tumors with chromosome 7 polysomy, white bars
represent percentage of tumors without chromosome 7 polysomy;
(b) the number of tumor cells showing chromosome 7 polysomy is
declining with attenuation of EGFR immunohistochemical staining
(p = 0.004, one-way ANOVA).
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expression showed relationship with patient survival
(Figure 4). Log-rank test showed an association between
shorter patient survival and high EGFR protein expres-
sion only for continuous membranous EGFR staining
(p = 0.046), while it could not be found for total membra-
nous staining (p = 0.074) and % of EGFR membranous
staining (p = 0.168). Association of EGFR cH-score and
tH-score with cumulative proportion of patients surviv-
ing during the follow-up are shown in Figure 4. Univari-
ate survival analysis also showed nuclear grade and
pathological T stage to be significant predictive factors
(p < 0.001 and p = 0.003, respectively). However, on mul-
tivariate analysis, only nuclear grade remained significant
(p = 0.002, relative risk 3, 95% confidence interval 1.7-
5.3), while pathologic stage (p = 0.009, relative risk 1.5,
95% confidence interval 1-2.4) together with EGFR pro-
tein expression (p = 0.175, relative risk 1.3, 95% confi-
dence interval 0.9-1.9) showed no independent
prognostic value.
Discussion
Many studies were conducted in order to determine
whether EGFR protein overexpression or EGFR gene
amplification could select patients who would benefit
from anti EGFR therapy. Some clinical data do not sup-
port an association between EGFR immunohistochemical
expression and response to specific targeted therapies
[14]. On the contrary, a recent review by Martin et al.
underlines that EGFR gene copy number changes
detected by FISH analysis might be used as an effective
tool in the selection of patient treatment [4]. In addition,
many authors have shown that the immunohistochemis-
try based EGFR screening method is not strictly quantita-
tive and needs standardized criteria for evaluation
[8,22,23]. Thus, our study was undertaken and based on
more objective evaluation of EGFR expression with the
emphasis on comparison of protein expression value with
FISH analysis.
Results of this study suggested two conclusions: first,
that patients with strong EGFR membranous staining on
at least 10% of tumor cells or with strong complete mem-
brane staining on at least 5% of tumor cells have poorer
prognosis; and second, that EGFR overexpression is not
associated with gene amplification but most likely with
polysomy of chromosome 7. From the practical point of
view, we presume that these patients could possibly be
selected for anti-EGFR therapy.
According to some studies, immunohistochemical
expression of EGFR in RCC varies from 50% to 90% of
tumor cells [24-26]. In our study, the mean percentage of
positive cells, tH-score and cH-score was 29%, 30%, and
16%, respectively. Our results are somewhat lower when
compared with H-score of 79 reported by Kallio et al.
Figure 3 Chromosome 7 polysomy and membrane EGFR
protein expression determined as percentage of EGFR
immunohistochemicaly positive cells per tumor (%), EGFR total
H-score (tH-score) and EGFR continuous H-score (cH-score) in
clear cell renal cell carcinoma (CCRCC). Low and high categories
of EGFR immunohistochemical staining are designated according to
median cut off value. Student’s t-test is showing higher percentage
of tumor cells with chromosome 7 polysomy to be significantly
associated with high expression of all EGFR immunohistochemical
staining categories: (a) EGFR % (p = 0.001); (b) EGFR tH-score (p <
0.001); (c) EGFR cH-score (p < 0.001).
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[25], but it should be noted that our study included only
clear cell type of RCC, whereas the above mentioned
authors focused on a heterogeneous group of tumor
types. They also pinpointed papillary carcinomas to have
the highest mean value, 140, of EGFR H-score, in com-
parison with other tumor types. This observation points
to the importance of taking into account tumor heteroge-
neity when interpreting EGFR expression. The variability
of findings with respect to EGFR expression in RCC
could be explained by different histological types of study
tumors and different methodology of evaluation used
[23]. Langner et al. investigated whether heterogeneous
results of prognostic significance of EGFR immunohisto-
chemical findings in RCC were related to non-standar-
dized criteria for staining evaluation [8]. This group of
researchers took into consideration cytoplasmic EGFR
immunostaining, which was associated with poor prog-
nosis. We also examined cytoplasmic EGFR expression
but it was not taken into consideration for further
analysis because it was mainly weakly expressed in a low
percentage of tumor cells (ranging from 2% to 10%).
The significance of continuous membrane HER-2
staining has been well recognized and included in patho-
logical evaluation of breast cancer [27]. On the other
hand, to our knowledge, we could not find any study on
RCC where only complete membrane H-score of EGFR
expression was identified and compared with clinico-
pathologic data. According to the results obtained in our
study, the EGFR cH-scoring system should be taken into
account because of its prognostic value, which is also
supported by chromosomal abnormalities found by FISH
analysis. Further investigations may shed more light on
its therapeutic significance.
Studies investigating the prognostic value of EGFR
expression in RCC show controversial results. In most
studies, the high EGFR expression was associated with
worse clinicopathologic prognostic parameters [28,29],
as it was observed in the head and neck tumors, breast,
Table 2 EGFR immunoexpression in relation to pathohistologic features of CCRCC (N = 94)
Nuclear grade,
N (%)
p value Tumor size,
median (range)
p value Pathological T stage,
N (%)
p value
1, 2 3, 4 1, 2 3, 4
EGFR immunoexpression a,N (%) % low 33 (36.7) 12 (13.3) < 0.001b 5 (1.8-17.5) 0.011c 32 (35.6) 13 (14.4) 0.213b
high 16 (17.8) 29 (32.2) 7 (3-16) 37 (41.1) 8 (8.9)
tH-score low 32 (35.9) 11 (12.4) < 0.001b 5 (1.8-17.5) 0.002c 31 (34.8) 12 (13.5) 0.354b
high 17 (19.1) 29 (32.6) 7 (3-16) 37 (41.6) 9 (10.1)
cH-score low 31 (34.4) 14 (15.6) 0.006b 5 (1.8-17.5) 0.01c 33 (36.7) 12 (13.3) 0.454b
high 18 (20) 27 (30) 7 (2.5-16) 36 (40) 9 (10)
CCRCC, clear cell renal cell carcinoma
tH-score, total H-score
cH-score, continuous H-score
a low and high categories according to median cut off value
b chi square test
c Mann-Whitney U-test
Figure 4 Kaplan-Meier survival analysis according to EGFR protein expression determined as H-score of continuous
immunohistochemical staining (cH-score) and total immunohistochemical staining (tH-score) in clear cell renal cell carcinoma (CCRCC):
(a) The log-rank test showed significantly shorter overall survival in patients with tumors showing high continuous EGFR protein expression that
was above median H-score values (p = 0.046). The 5-year survival rate was 59% for patients whose tumors showed low EGFR cH-score vs. 40%
for patients whose tumors showed high EGFR cH-score; (b) on the contrary, the log-rank test showed no significant association between EGFR
tH-score and survival (p = 0.074). The 5-year survival rate was 57% for patients whose tumors showed low EGFR tH-score and 40% for patients
whose tumors showed high EGFR tH-score.
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lung and bladder cancer [4,30]. On the other hand, the
minority of studies showed opposite results, or do not
confirm the significant prognostic role of EGFR overex-
pression [15,16,25]. In relation to the clinical and patho-
logical parameters, our univariate analysis confirmed
both high tH-score and high cH-score to be associated
with higher nuclear grade and larger tumor size. In con-
trast to our results, Kallio et al. found an association
between higher EGFR expression and lower nuclear
grade [25]. However, neither this nor our study found
any connection between EGFR expression and tumor
stage. The prognostic significance of EGFR expression
was also confirmed in our survival analysis, however,
only when the percentage of positive cells was estimated
in association with staining intensity. Namely, the over-
all survival of patients with predominantly high EGFR
cH-score expression was shorter. These results are in
agreement with others studies in which strong mem-
brane EGFR expression was significantly associated with
worse survival [8,29,31].
The most common gene alteration that results in
excessive expression of EGFR is amplification. Nonethe-
less, our FISH analysis confirmed that tumors with low
or moderate EGFR membrane expression had no parti-
cular changes in the number of chromosome copies,
and that those with strong EGFR expression had no
gene amplification, as observed by some other authors
[21,32]. On the other hand, chromosome 7 polysomy
found by FISH analysis in our study was associated with
strong and mostly continuous membrane expression, as
also reported elsewhere [33].
Conclusion
In conclusion, the EGFR protein expression has an
impact on prognosis, i.e. a higher expression correlates
with a higher nuclear grade and larger tumors, and
strong continuous membrane immunostaining is signifi-
cantly associated with shorter survival of patients with
CCRCC. Increased copy numbers of chromosome 7
could be the source of overall EGFR expression at the
protein level.
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